Elimination of the initiating event in leukemogenesis has proved to be an extremely effective therapeutic strategy, such as Gleevec for BCR‐ABL in chronical myeloid leukaemia51 and all‐trans retinoic acid for AML with PML‐RARα.52 These therapeutic strategies have produced tremendous advances in the treatment of AML patients. The gene discussed is RARA; the disease is acute myeloid leukemia.